Search Results

You are looking at 1 - 10 of 71 items for :

  • User-accessible content x
Clear All
Full access

Gary H. Lyman and David C. Dale

granulocyte colony-stimulating factor (G-CSF). This article focuses on the long-term benefits and risks associated with G-CSF therapy, including data for other myeloid factors, as available. Chemotherapy-Induced Neutropenia G-CSF reduces neutropenic

Full access

Gary H. Lyman and Marek S. Poniewierski

treatment delays, and subsequently compromise disease control and overall survival. 2 – 6 The myeloid growth factors (MGFs), including granulocyte colony-stimulating factor (G-CSF), have been shown to decrease the risk of neutropenic complications

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel and Chun Chao

, chemotherapy agents, or cycle length; (2) received prophylactic granulocyte colony-stimulating factor (G-CSF) within 4 days of chemotherapy initiation and/or antibiotics prophylaxis dispensed between 3 days before and 10 days after first chemotherapy

Full access

Olga Frankfurt and Martin S. Tallman

-metHuG-CSF): the first 10 years . Blood 1996 ; 88 : 1907 – 1929 . 2. Spiekermann K Roesler J Emmendoerffer A . Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications . Leukemia 1997

Full access

David C. Dale

Hematol 1989 ; 26 : 7 – 14 . 15 Dale DC Bonilla MA Davis MW . A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia . Blood 1993 ; 181 : 2496 – 2502 . 16 Smith TJ

Full access

Lee S. Schwartzberg and Sarah L. Blair

: AC, anthracycline/cyclophosphamide; CMF, cyclophosphamide/methotrexate/fluorouracil; doc, docetaxel; G-CSF, granulocyte colony-stimulating factor; pts, patients; T, paclitaxel; TC, docetaxel/cyclophosphamide; TCH, docetaxel

Full access

Adam J. Olszewski, Kalyan C. Mantripragada and Jorge J. Castillo

identified prophylactic granulocyte colony-stimulating factor (G-CSF) administration during the first cycle. 24 The primary outcome of analysis was death within 30 days from chemotherapy initiation. The secondary outcome was hospitalization. We also

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

cost. 2 Prophylactic use of recombinant human granulocyte colony-stimulating factors (G-CSFs), such as filgrastim or pegfilgrastim, can significantly reduce FN risk and FN-related costs. 3 – 5 The risk of developing FN depends on patient and disease

Full access

Jacqueline N. Poston and Pamela S. Becker

of the protected marrow microenvironment, rendering them more susceptible to chemotherapy. One preclinical study found that granulocyte colony-stimulating factor (G-CSF) reduced the viability of AML cells in vitro when cocultured with HS-5 stroma

Full access

Pamela S. Becker

dosing of cytokines and receptor antagonists. Granulocyte colony-stimulating factor (G-CSF) causes release of proteases, including neutrophil elastase, which cleaves CXCR4 and VCAM-1, 8 , 9 and elevated levels of metalloproteinases, including MMP-2 (that